DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 16.16
(0.56%)
CNY 16.16
(0.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.17 Billion CNY | 15.7% |
| 2022 | 13.97 Billion CNY | 22.61% |
| 2021 | 11.39 Billion CNY | 68.66% |
| 2020 | 6.75 Billion CNY | 55.73% |
| 2019 | 4.34 Billion CNY | 25.79% |
| 2018 | 3.45 Billion CNY | 14.25% |
| 2017 | 3.02 Billion CNY | 34.94% |
| 2016 | 2.23 Billion CNY | 36.7% |
| 2015 | 1.63 Billion CNY | -8.55% |
| 2014 | 1.79 Billion CNY | 64.11% |
| 2013 | 1.09 Billion CNY | 77.27% |
| 2012 | 615.39 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 17.75 Billion CNY | 2.7% |
| 2024 Q1 | 16.9 Billion CNY | 4.56% |
| 2024 Q2 | 17.28 Billion CNY | 2.25% |
| 2023 Q2 | 13.19 Billion CNY | -2.77% |
| 2023 Q3 | 13.56 Billion CNY | 2.77% |
| 2023 Q4 | 16.17 Billion CNY | 19.24% |
| 2023 FY | 16.17 Billion CNY | 15.7% |
| 2023 Q1 | 13.57 Billion CNY | -2.9% |
| 2022 Q4 | 13.97 Billion CNY | 20.44% |
| 2022 Q3 | 11.6 Billion CNY | 0.04% |
| 2022 Q1 | 11.3 Billion CNY | -0.8% |
| 2022 FY | 13.97 Billion CNY | 22.61% |
| 2022 Q2 | 11.59 Billion CNY | 2.57% |
| 2021 Q4 | 11.39 Billion CNY | 11.61% |
| 2021 FY | 11.39 Billion CNY | 68.66% |
| 2021 Q2 | 9.97 Billion CNY | 2.51% |
| 2021 Q1 | 9.72 Billion CNY | 43.95% |
| 2021 Q3 | 10.21 Billion CNY | 2.41% |
| 2020 Q1 | 4.32 Billion CNY | -0.26% |
| 2020 Q2 | 4.19 Billion CNY | -3.1% |
| 2020 Q4 | 6.75 Billion CNY | 41.75% |
| 2020 FY | 6.75 Billion CNY | 55.73% |
| 2020 Q3 | 4.76 Billion CNY | 13.67% |
| 2019 Q1 | 3.62 Billion CNY | 5.05% |
| 2019 FY | 4.34 Billion CNY | 25.79% |
| 2019 Q2 | 4.29 Billion CNY | 18.57% |
| 2019 Q4 | 4.34 Billion CNY | 0.23% |
| 2019 Q3 | 4.33 Billion CNY | 0.76% |
| 2018 Q1 | 2.7 Billion CNY | -10.56% |
| 2018 Q2 | 2.9 Billion CNY | 7.52% |
| 2018 Q3 | 3.38 Billion CNY | 16.73% |
| 2018 Q4 | 3.45 Billion CNY | 1.78% |
| 2018 FY | 3.45 Billion CNY | 14.25% |
| 2017 Q4 | 3.02 Billion CNY | 15.7% |
| 2017 Q2 | 2.37 Billion CNY | 6.42% |
| 2017 Q3 | 2.61 Billion CNY | 9.9% |
| 2017 Q1 | 2.23 Billion CNY | -0.27% |
| 2017 FY | 3.02 Billion CNY | 34.94% |
| 2016 FY | 2.23 Billion CNY | 36.7% |
| 2016 Q4 | 2.23 Billion CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2015 FY | 1.63 Billion CNY | -8.55% |
| 2015 Q4 | 1.63 Billion CNY | 0.0% |
| 2015 Q1 | 1.59 Billion CNY | 0.0% |
| 2015 Q2 | 1.59 Billion CNY | 0.0% |
| 2014 FY | 1.79 Billion CNY | 64.11% |
| 2013 FY | 1.09 Billion CNY | 77.27% |
| 2012 FY | 615.39 Million CNY | 0.0% |